Genomes and Genes
Anneke van der Walt
Affiliation: Royal Melbourne Hospital
- A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremorAnneke van der Walt
Royal Melbourne Hospital, Melbourne, Australia
Neurology 79:92-9. 2012..To evaluate the safety and efficacy of botulinum toxin type A in disabling multiple sclerosis (MS)-related upper limb tremor...
- Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophyA van der Walt
Royal Melbourne Hospital, Department of Neurology, Parkville, Vic, Australia
Neurology 73:1018-25. 2009..In this study, we examine the influence of heterogeneity of the APOE gene on disease severity in a large, Australian, population-based MS cohort...
- Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decadeAnneke van der Walt
The Royal Melbourne Hospital, Grattan St Parkville, Melbourne, Australia Centre for Neuroscience, University of Melbourne, Australia
Pharmacol Ther 126:82-93. 2010..In this article, we will discuss some of the principal therapeutic candidates that could provide neuroprotection in MS and emerging methodologies by which to test them...
- Heterogeneity at the HLA-DRB1 allelic variation locus does not influence multiple sclerosis disease severity, brain atrophy or cognitionAnneke van der Walt
Department of Neurology, The Royal Melbourne Hospital, Melbourne, Australia
Mult Scler 17:344-52. 2011..We examined the influence of DR15 and other common DRB1 alleles (DRB1*01 (DR1), DRB1*03 (DR3) and DRB1*04 (DR4) on MS severity in a large, Australian, population-based cohort...
- Optic nerve diffusion tensor imaging after acute optic neuritis predicts axonal and visual outcomesAnneke van der Walt
Department of Anatomy and Neuroscience, University of Melbourne, Melbourne, Victoria, Australia Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia Department of Neuro ophthalmology, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia Melbourne Brain Centre at Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia
PLoS ONE 8:e83825. 2013..Early markers of axonal and clinical outcomes are required for early phase testing of putative neuroprotective therapies for multiple sclerosis (MS)...
- Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patientsCathy J Jensen
Howard Florey Institute, Melbourne, Australia
PLoS ONE 5:e10003. 2010..No associations were significant after correction for multiple testing. We found no evidence for the hypothesis that these new MS disease risk-associated SNPs influence disease severity...
- Optic nerve magnetisation transfer ratio after acute optic neuritis predicts axonal and visual outcomesYejun Wang
The Centre for Neuroscience Research, University of Melbourne, Parkville, Victoria, Australia
PLoS ONE 7:e52291. 2012..59, p = 0.02). In conclusion, these findings indicate that MTR flux after acute ON is predictive of axonal degeneration and visual disability outcomes...
- Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosisTomas Kalincik
Departments of Medicine and Neurology, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia
PLoS ONE 8:e63480. 2013....